Scorpius Holdings selected for RRPV to accelerate countermeasure development

Scorpius Holdings has been selected as a member of the Biomedical Advanced Research and Development Authority’s Rapid Response Partnership Vehicle. The RRPV supports BARDA in its mission to accelerate the development of medical countermeasures to address emerging biological threats such as pandemic influenza, infectious diseases, and other public health emergencies. As an active member of the RRPV, Scorpius will collaborate with BARDA and other federal partners to support MCM product and technology development in critical areas such as vaccines and therapeutics. Scorpius’ extensive capabilities in biomanufacturing and its state-of-the-art production facilities should uniquely position it to meet the evolving needs of government agencies tasked with responding to biological threats.